[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200870535A1 - СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig - Google Patents

СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig

Info

Publication number
EA200870535A1
EA200870535A1 EA200870535A EA200870535A EA200870535A1 EA 200870535 A1 EA200870535 A1 EA 200870535A1 EA 200870535 A EA200870535 A EA 200870535A EA 200870535 A EA200870535 A EA 200870535A EA 200870535 A1 EA200870535 A1 EA 200870535A1
Authority
EA
Eurasian Patent Office
Prior art keywords
taci
molecule
treatment
autoimmune diseases
methods
Prior art date
Application number
EA200870535A
Other languages
English (en)
Other versions
EA015342B1 (ru
Inventor
Эрве Броли
Шарон Басби
Джейн Гросс
Дженнифер Висич
Иван Нестеров
Original Assignee
Арес Трейдинг С.А.
Займоджинетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арес Трейдинг С.А., Займоджинетикс, Инк. filed Critical Арес Трейдинг С.А.
Publication of EA200870535A1 publication Critical patent/EA200870535A1/ru
Publication of EA015342B1 publication Critical patent/EA015342B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В различных вариантах осуществления настоящее изобретение обеспечивает способы и композиции для лечения аутоиммунных заболеваний, в том числе ревматоидного артрита, например, предусматривающие введение нуждающемуся в таком лечении пациенту слитой молекулы TACI-Ig. В одном варианте осуществления слитую молекулу TACI-Ig вводят в количестве, достаточном для замедления, супрессии или ингибирования индуцирующих пролиферацию функций BlyS и APRIL.
EA200870535A 2006-05-15 2007-05-15 Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig EA015342B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74727006P 2006-05-15 2006-05-15
PCT/US2007/068982 WO2007134326A2 (en) 2006-05-15 2007-05-15 Methods for treating autoimmune diseases using a taci-ig fusion molecule

Publications (2)

Publication Number Publication Date
EA200870535A1 true EA200870535A1 (ru) 2009-04-28
EA015342B1 EA015342B1 (ru) 2011-06-30

Family

ID=38694783

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870535A EA015342B1 (ru) 2006-05-15 2007-05-15 Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig

Country Status (17)

Country Link
US (1) US8784812B2 (ru)
EP (1) EP2035028A2 (ru)
JP (2) JP2009537563A (ru)
KR (1) KR20090016707A (ru)
CN (1) CN101489573B (ru)
AR (1) AR060935A1 (ru)
AU (1) AU2007249223B2 (ru)
BR (1) BRPI0711823A2 (ru)
CA (1) CA2651791A1 (ru)
EA (1) EA015342B1 (ru)
EC (1) ECSP088982A (ru)
IL (1) IL195243A0 (ru)
MX (1) MX2008014365A (ru)
NZ (1) NZ572373A (ru)
UA (1) UA98462C2 (ru)
WO (1) WO2007134326A2 (ru)
ZA (1) ZA200809202B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139517B1 (en) 2007-03-27 2013-05-29 Zymogenetics, Inc. Combination of blys inhibition and mycophenolate mofetil for treatment of autoimmune disease
WO2008157369A2 (en) * 2007-06-13 2008-12-24 Zymogenetics, Inc. Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
US8956611B2 (en) * 2007-10-16 2015-02-17 Zymogenetics, Inc. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
WO2011109280A1 (en) * 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US9895064B2 (en) * 2010-11-26 2018-02-20 Hemics B.V. Device and method for determining a disease activity
WO2016003876A1 (en) 2014-07-03 2016-01-07 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
AU2021267276B2 (en) 2020-05-08 2024-10-24 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
AU2022269139A1 (en) * 2021-05-07 2023-11-16 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
KR20240014066A (ko) * 2021-09-30 2024-01-31 레메젠 코, 리미티드 Taci-fc 융합 단백질을 사용하여 쇼그렌 증후군을 치료하는 방법
WO2024159715A1 (zh) * 2023-01-31 2024-08-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗IgG4相关性疾病的方法

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE3578435D1 (de) 1984-12-06 1990-08-02 Labofina Sa Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
DE721983T1 (de) 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
ATE196310T1 (de) 1990-02-09 2000-09-15 Salk Inst For Biological Studi Retinoid-rezeptor-zusammensetzungen und verfahren
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
AU5103293A (en) 1992-09-14 1994-04-12 Oklahoma State University Immortalized cells and uses therefor
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5650550A (en) 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5523227A (en) 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
JP3787355B2 (ja) 1994-12-15 2006-06-21 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｆａｓ／ａｐｏ１受容体機能のモジュレーター
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19533447C1 (de) 1995-09-09 1996-12-05 Bbs Kraftfahrzeugtechnik Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
AU712650B2 (en) 1995-11-09 1999-11-11 Zymogenetics Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
EP1362916A3 (en) 1996-03-14 2004-02-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
WO1998055621A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
IL134480A0 (en) 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
CA2303615A1 (en) 1997-09-12 1999-03-18 Jurg Tschopp April- a novel protein with growth effects
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
DE19831987A1 (de) 1998-07-16 2000-01-20 Bayer Ag Diphenylimidazoline
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
CA2357950C (en) 1998-12-30 2013-07-23 Oligo Therapeutics Inc. Therapeutic phosphodiesterase inhibitors
PL211033B1 (pl) 1999-01-07 2012-04-30 Zymogenetics Inc Zastosowanie związku będącego polipeptydem do wytwarzania leku, zastosowanie przeciwciała lub fragmentu przeciwciała do wytwarzania leku oraz zastosowanie przeciwciała lub fragmentu przeciwciała do hamowania wytwarzania przeciwciała związanego z toczniem rumieniowatym układowym
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
KR100834809B1 (ko) 1999-01-25 2008-06-05 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ, 관련 차단제 및 면역 반응에서 ｂ 세포와면역글로불린을 촉진 및 억제하는데에 있어서 이들의 용도
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
CA2374597A1 (en) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
GEP20053685B (en) 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
UA74798C2 (ru) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Способ лечения рака у млекопитающих с помощью полипептида, который препятствует взаимодействию между april и его рецепторами
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
ATE336509T1 (de) 2000-04-27 2006-09-15 Biogen Idec Inc Verwendung von taci als antitumormittel
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
CN101275136A (zh) 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
ATE432986T1 (de) 2000-11-07 2009-06-15 Zymogenetics Inc Menschlicher rezeptor für tumor necrosis factor
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
KR100976743B1 (ko) * 2001-05-24 2010-08-19 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
BR0211614A (pt) 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
WO2003097040A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AU2004251679C1 (en) * 2003-06-05 2009-05-28 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
RU2006117324A (ru) * 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
UA93516C2 (ru) 2005-08-09 2011-02-25 Займоджинетикс, Инк. Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig

Also Published As

Publication number Publication date
WO2007134326A3 (en) 2008-04-17
EA015342B1 (ru) 2011-06-30
ECSP088982A (es) 2009-01-30
AU2007249223A1 (en) 2007-11-22
WO2007134326A2 (en) 2007-11-22
KR20090016707A (ko) 2009-02-17
EP2035028A2 (en) 2009-03-18
CN101489573A (zh) 2009-07-22
JP2013100313A (ja) 2013-05-23
US8784812B2 (en) 2014-07-22
IL195243A0 (en) 2011-08-01
AU2007249223B2 (en) 2012-08-02
AR060935A1 (es) 2008-07-23
JP2009537563A (ja) 2009-10-29
US20070274984A1 (en) 2007-11-29
UA98462C2 (ru) 2012-05-25
MX2008014365A (es) 2008-11-27
NZ572373A (en) 2012-02-24
BRPI0711823A2 (pt) 2012-01-17
ZA200809202B (en) 2009-12-30
CN101489573B (zh) 2013-05-22
CA2651791A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
EA200870535A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
EA200802204A1 (ru) Применение ингибиторов dpp iv
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA200970224A1 (ru) Лечение заболеваний хряща
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
EA200970342A1 (ru) Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
EA200970446A1 (ru) Связывающиеся с альбумином молекулы и их применение
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
TN2009000095A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
TW200806299A (en) Treatment of pain
EA200500782A1 (ru) Лечение геморрагического шока
EA200801997A1 (ru) Новые соединения
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
TW200639159A (en) Treatment of pain
EA200701594A1 (ru) Лакозамид для дополнительной терапии
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MY148277A (en) Treatment of cartilage disorders with fgf-18
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU